Episode 277
In 2023, you’d be hard-pressed to find a Wall Street analyst who wasn’t in love with Lululemon. The stock was a classic example of a long-term, buy-and-hold winner, with a strong brand, enviable prof…
Published on 11 hours ago
Episode 276
This week, we bring you a debate every investor has had over the last year: Is Tesla still a buy?
Mike starts off by breaking down the brand’s difficulties in Europe, with sales sliding across markets…
Published on 1 week ago
Episode 275
Mike and Emmet are back from Investicon with two phenomenal stock picks shared by the event’s expert panel.
Mike breaks down Chapters Group (ETR: CHG), a vertical market software acquirer modeled afte…
Published on 2 weeks ago
We're discussing two very different stocks today on Stock Club. One is the hottest stock on the market and one of the few companies being absolutely transformed by AI. Up 500% in the last year and al…
Published on 4 weeks ago
Episode 273
Novo Nordisk faced another tough earnings season, with the stock falling 30% after it revised its growth guidance due to increased competition from Eli Lilly and the (now-illegal) compounders. This h…
Published on 1 month ago
Episode 272
This week, Mike sits down with Emma Farrelly, a Qualified Financial Adviser (QFA) and Retirement Planning Adviser (RPA) from Future Financial Planning in Dublin.
Emma walks through what every twenty-s…
Published on 1 month, 1 week ago
Episode 271
This week, Emmet is joined by legendary investor Chris Hill. Chris was one of the Motley Fool’s longest-standing employees, contributing 26 years of expertise and stock pitches. He was the host of th…
Published on 1 month, 2 weeks ago
Episode 270
Mike is joined by Clem Chambers, financial journalist, author, and contributor to Forbes, Fox, and Wired.
Clem is a self-described contrarian investor who seeks opportunities in inefficient markets. T…
Published on 1 month, 3 weeks ago
Episode 235
The IPO market has been a barren wasteland since the carefree days of 2020. But this week, we bring you an IPO that might actually be worth a look.
Figma has released its hotly anticipated S-1, reveal…
Published on 2 months ago
Season 268
Anne Marie and Mike are back and they are here to pitch two big name stocks trading on the cheap.
First up: Novo Nordisk. The Ozempic darling soared in 2024, but tough competition from Eli Lilly and a…
Published on 2 months, 1 week ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate